EGFR and non-small cell lung carcinoma: Sunvozertinib, a selective small molecule inhibitor of EGFR exon20ins, has exhibited remarkable antitumor activity in a pivotal study, with a confirmed ORR of 60.8% among Chinese NSCLC patients harboring these mutations (30, 31).